How should we measure the impact of chronic pain? Limitations of utility measurement using the EQ-5D and SF-6D

被引：6
|
作者：
Schofield, Deborah J. [1 ,2 ]
机构：
[1] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW 1450, Australia
[2] Univ Sydney, Sch Publ Hlth, Camperdown, NSW 1450, Australia
来源：
PAIN | 2014年 / 155卷 / 10期
关键词：
PREFERENCE-BASED MEASURE; HEALTH; PATIENT;
D O I：
10.1016/j.pain.2014.07.020
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
引用
收藏
页码：1918 / 1919
页数：2
相关论文
共 50 条
  • [41] Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D
    Walters, SJ
    Brazier, JE
    QUALITY OF LIFE RESEARCH, 2005, 14 (06) : 1523 - 1532
  • [42] Mapping utility scores from the EQ-5D and SF-6D onto the schizophrenia quality of life scale
    Clayson, DJ
    Briggs, AH
    Sculpher, M
    De Hert, M
    VALUE IN HEALTH, 2004, 7 (03) : 277 - 277
  • [43] A comparison of the measurement properties and estimation of minimal important differences of the EQ-5D and SF-6D utility measures in patients with systemic sclerosis
    Kwakkenbos, L.
    Fransen, J.
    Vonk, M. C.
    Becker, E. S.
    Jeurissen, M.
    van den Hoogen, F. H. J.
    van den Ende, C. H. M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (02) : S50 - S56
  • [44] The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis
    M. J. Harrison
    L. M. Davies
    N. J. Bansback
    M. J. McCoy
    S. M. M. Verstappen
    K. Watson
    D. P. M. Symmons
    Quality of Life Research, 2009, 18 : 1195 - 1205
  • [45] A CALIBRATION OF THE RELATIONSHIP BETWEEN THE HAQ, THE SF-6D AND THE EQ-5D IN INFLAMMATORY ARTHRITIS
    Adams, R.
    Walsh, C.
    Tilson, L.
    FitzGerald, O.
    Bresnihan, B.
    Veale, D.
    Barry, M.
    VALUE IN HEALTH, 2009, 12 (07) : A446 - A447
  • [46] Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens
    Stepanova, M.
    Nader, F.
    Cure, S.
    Bourhis, F.
    Hunt, S.
    Younossi, Z. M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (06) : 676 - 685
  • [47] EQ-5D versus SF-6D in an older, chronically ill patient group
    Gerard K.
    Nicholson T.
    Mullee M.
    Mehta R.
    Roderick P.
    Applied Health Economics and Health Policy, 2004, 3 (2) : 91 - 102
  • [48] IMPACT OF COMORBIDITIES ON MEASURING INDIRECT UTILITY BY THE SF-6D OR THE EQ-5D IN RHEUMATOID ARTHRITIS: AN ANALYSIS OF 962 PATIENTS ENROLLED IN COMEDRA
    Gaujoux-Viala, C.
    Hosseini, K.
    Rat, A. -C.
    Guillemin, F.
    Etcheto, A.
    Soubrier, M.
    Fautrel, B.
    Dougados, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 332 - 332
  • [49] The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis
    Harrison, M. J.
    Davies, L. M.
    Bansback, N. J.
    McCoy, M. J.
    Verstappen, S. M. M.
    Watson, K.
    Symmons, D. P. M.
    QUALITY OF LIFE RESEARCH, 2009, 18 (09) : 1195 - 1205
  • [50] A comparison of the performance of the EQ-5D and SF-6D for individuals aged ≥ 45 years
    Barton, Garry R.
    Sach, Tracey H.
    Avery, Anthony J.
    Jenkinson, Claire
    Doherty, Michael
    Whynes, David K.
    Muir, Kenneth R.
    HEALTH ECONOMICS, 2008, 17 (07) : 815 - 832
12345